西藏藥業(600211.SH):公司在上海建設的疫苗生產線已轉固
格隆匯2月10日丨西藏藥業(600211.SH)投資者關係活動記錄表顯示,公司在上海建設的疫苗生產線已轉固,將按照相關會計政策計提折舊。目前公司正在利用該生產線進行一些項目的工藝優化研究。
2023年度公司聘請了第三方評估機構就斯微股權進行了評估,估值報吿顯示該股權的公允價值為1000萬元。按照相關會計政策規定,公司會在年末資產負債表日進行減值測試,判斷該項資產是否存在減值跡象,並根據測試情況確定是否減值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.